Global Apixaban Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado apixabana

Projeta-se que o mercado observe um grande crescimento durante o período de previsão. A apixabana está geralmente indicada para reduzir o risco de acidente vascular cerebral e embolia sistémica em doentes com fibrilhação auricular não valvular. A dose recomendada de Eliquis é de 5 mg por via oral, duas vezes por dia. A apixabana está disponível no mercado em cápsulas e comprimidos. O desenvolvimento de anticoagulantes avançados aumenta a procura e oferece inúmeras opções aos doentes e aos profissionais de saúde.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de apixabana no período de previsão 2023-2030. O CAGR esperado do mercado global de apixabana tende a rondar os 5,70% no período de previsão mencionado. O mercado foi avaliado em 1.765,8 milhões de dólares em 2022 e cresceria para 2.908,17 milhões de dólares até 2030. Para além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge, também inclui análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado apixabana

Definição de mercado

A apixabana é um anticoagulante aprovado pela FDA utilizado para o tratamento de eventos tromboembólicos venosos que se formam no interior de uma veia. Os eventos tromboembólicos venosos (TEV) podem ocorrer sem quaisquer sintomas típicos ou sinais de alerta. Os sintomas comuns associados à trombose venosa profunda (TVP) ou à embolia pulmonar (EP) são dor no peito, dor no gémeo, vermelhidão ou manchas de descoloração visíveis, inchaço no tornozelo ou no pé e outros.

Dinâmica global do mercado da apixabana

Motoristas

• Aumento da prevalência de tromboembolismo venoso

Prevê-se que a crescente prevalência de condições relacionadas com o tromboembolismo venoso ajude a fazer crescer o mercado. De acordo com a American Heart Association, o TEV afeta cerca de 300.000 a 600.000 americanos anualmente. Os registos da Sociedade Internacional de Trombose e Hemostasia de 2014 revelaram que cerca de 10 milhões de casos de tromboembolismo venoso ocorrem anualmente em países de baixo, médio e alto rendimento. Assim, atua como um importante impulsionador do crescimento do mercado.

• Aumento dos medicamentos aprovados pela FDA       

O desenvolvimento de vários anticoagulantes avançados aumenta a procura e oferece inúmeras opções aos doentes e aos profissionais de saúde. A Apixabana foi submetida a grandes ensaios clínicos e recebeu aprovação da FDA para diversas indicações. A apixabana é um anticoagulante significativo que atua bloqueando certas proteínas de coagulação do sangue.

Oportunidades

• Aumento do desenvolvimento de I&D

Tem havido um desenvolvimento crescente na frente final da investigação, criando muitas oportunidades de crescimento do mercado. Por exemplo, o ensaio ARISTOTLE mostrou que a apixabana é superior à varfarina na redução do acidente vascular cerebral e da embolia sistémica em doentes com fibrilhação auricular. A Pfizer colaborou com a Bristol-Myers Squibb para desenvolver e comercializar o apixabano; a aliança fortalece ambas as empresas para expandir o potencial no desenvolvimento e comercialização de medicamentos cardiovasculares.  

• Presença de alternativa económica

The apixaban is the third non-vitamin K antagonist oral anticoagulant used for clinical practice. The regular dose of apixaban is highly effective in decreasing thromboembolic events compared to warfarin. In December 2019, the US FDA approved the first generics of apixaban tablets, and FDA's generic drug program enables access to cost-effective and high-quality drugs

Restraints/Challenges

• Side effects of apixaban

Several adverse effects of apixaban, such as the increased risk of thrombotic events after premature discontinuation and bleeding, are projected to hamper this drug's usage. This, in turn, is estimated to adversely affect the market's growth.

• Unavailability of appropriate treatments

To treat conditions that are rare, several times, all treatments are not available, particularly in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.

This global apixaban market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global apixaban market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Apixaban Market

The COVID-19 pandemic significantly impacted the global apixaban market. COVID-19 patients often develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm, and complement cascade hyperactivation. Numerous medications are being used for the treatment of COVID-19 patients. Sarilumab and tocilizumab can increase cytochrome P450 enzyme activity, so they should not be used together with apixaban or rivaroxaban and may also increase the doses of warfarin required. The thrombotic risk is linked with disease severity and worsens patients' prognosis; the management strategies need to be assessed.

Global Apixaban Market Scope

The global apixaban market is segmented on the basis of dosage form, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Dosage Form

• Capsule
• Tablets 

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Apixaban Market Regional Analysis/Insights

The global apixaban market is analysed and market size insights and trends are provided by dosage form,end-user, distribution channel as referenced above.

The major countries covered in the global apixaban market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the highest investment in healthcare and awareness.

Asia-Pacific is considered to have the most lucrative period because of the developing healthcare facilities, large number of generic manufacturers, and increase in government initiatives

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Apixaban Market Share Analysis

The global apixaban market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global apixaban market.

Key players operating in the global apixaban market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France), Pfizer Inc. (US.)
• GSK plc (UK.)
• Novartis AG (Switzerland)
• AstraZeneca (UK.)
• Johnson & Johnson Private Limited (US.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (US.)
• Bristol-Myers Squibb Company (US.)
• Lilly (US.)
• Amgen Inc. (US.)
• Eisai Co., Ltd (Japan)
• Aspen Holdings (South Africa)
• Fresenius Kabi AG (Germany)
• Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
• OPOCRIN SPA (Italy)
• SARIA International GmbH (Germany)
• Hepalink Group (China).
• Shenzhen Techdow Pharmaceutical Co., Ltd (China)
• Yino Pharma Limited (China)

SKU-59570